目的合成选择性雌激素受体调节剂盐酸雷洛昔芬。
Objective To synthesize raloxifene hydrochloride, which is a selective estrogen receptor modulator.
目的选择性雌激素受体调节剂对去势大鼠松质骨、皮质骨骨密度的影响。
AIM to discuss the influence of selective estrogen receptor modulator (SERM) on bone mineral density loss in cancellated bone and compact bone of ovariectomized rats.
目的观察雌二醇、结合雌激素和雌激素受体调节剂对去卵巢大鼠摄食行为的影响。
ObjectiveTo investigate the effects of the estradiol, conjugated estrogen and raloxifene on the food intake behavior, locomotor activity and sucrose choice in the ovariectomized rats.
雷洛昔芬(Evista)是一种选择性雌激素受体调节剂，可以用来防治骨质疏松症。
C. Raloxifene (Evista) is a selective estrogen receptor modulator. It is available for prevention and treatment of osteoporosis.
目的：探讨选择性雌激素受体调节剂雷洛昔芬对去卵巢大鼠血压、血脂、纤维蛋白原和雌激素受体的作用。
Objective: To investigate the effect of raloxifene, a selective estrogen receptor modulator, on blood pressure, lipid, fibrinogen and estrogen receptor in ovariectomized rats.
综述近几年上市或开发中的雌激素受体调节剂类药物，主要包括选择性雌激素受体调节剂和纯抗雌激素药物。
The estrogen receptor modulator drugs launched or developed in recent years were reviewed, mainly including selective estrogen receptor modulators and pure antiestrogen.
选择性雌激素受体调节剂是一类在不同的组织细胞中对雌激素受体发挥不同调节作用的化合物，用于治疗绝经后妇女的骨质疏松和乳腺癌等。
Selective estrogen receptor modulators (SERMs) are kinds of compounds that exert different biological effects on er in different tissues and can be used in the tr.
选择性雌激素受体调节剂使用者症状出现的比值比为1.39 (95%CI 1.22 - 1.59)，而使用非处方激素的妇女1.37 (9 5% CI 1.16 - 1.62)。
For GERD symptoms, or was 1.39 (95% CI, 1.22-1.59) for current SERM users and 1.37 (95% CI, 1.16-1.62) for women currently using OTC hormone preparations.
选择性雌激素受体调节剂使用者症状出现的比值比为1.39 (95%CI 1.22 - 1.59)，而使用非处方激素的妇女1.37 (9 5% CI 1.16 - 1.62)。
For GERD symptoms, or was 1.39 (95% CI, 1.22-1.59) for current SERM users and 1.37 (95% CI, 1.16-1.62) for women currently using OTC hormone preparations.
应用推荐